Egesta Lopci

List of Publications by Year
in descending order

161 papers	3,939 citations	147801 31 h-index	155660 55 g-index
167 all docs	167 docs citations	167 times ranked	5760 citing authors

#	Article	IF	Citations
1	The Role of Radiomics in the Era of Immune Checkpoint Inhibitors: A New Protagonist in the Jungle of Response Criteria. Journal of Clinical Medicine, 2022, 11, 1740.	2.4	15
2	Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors. European Radiology, 2022, , 1.	4.5	2
3	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2323-2341.	6.4	48
4	Advances in Lung Cancer Imaging and Therapy. Cancers, 2022, 14, 58.	3.7	0
5	Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3852-3869.	6.4	14
6	Meditating on Cancer Management at the Time of Immunotherapy. Journal of Clinical Medicine, 2022, 11, 3025.	2.4	0
7	Re: Stefano Fanti, Alberto Briganti, Louise Emmett, et al. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy. Eur Urol Oncol. 2022;5:530â€“6. European Urology Oncology, 2022, 5, 601-602.	5.4	3
8	Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis. European Urology Focus, 2021, 7, 764-771.	3.1	32
9	Advancing Imaging to Enhance Surgery. Neurosurgery Clinics of North America, 2021, 32, 31-46.	1.7	7
10	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0
11	Additional value of volumetric and texture analysis on FDG PET assessment in paediatric Hodgkin lymphoma: an Italian multicentric study protocol. BMJ Open, 2021, 11, e041252.	1.9	5
12	Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors. Journal of Clinical Medicine, 2021, 10, 1251.	2.4	21
13	A Score for Predicting Freedom from Progression of Children and Adolescents with Hodgkin Lymphoma. Hemato, 2021, 2, 264-280.	0.6	0
14	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. Cancers, 2021, 13, 3117.	3.7	17
15	Mismatched Imaging Findings of Prostate Cancer Diagnosis: 68ÂGa-PSMA PET/CT vs mpMRI. Nuclear Medicine and Molecular Imaging, 2021, 55, 199-202.	1.0	2
16	Carcinomatosis peritoneal y metÃ¡stasis ocultas en el cÃ¡ncer de prÃ³stata: [68Ga]PSMA vs. [11C]Colina. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 261-262.	0.0	0
17	Peritoneal carcinomatosis and occult metastasis in prostate cancer: [68Ga]PSMA vs [11C]Choline. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2021, 40, 261-262.	0.2	0
18	Re: Hendrik Van Poppel, RenÃ©e Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. Eur Urol 2021;79:327â€“9. European Urology, 2021, 80, e24-e27.	1.9	0

#	Article	IF	Citations
19	â€œPET/CT Variants and Pitfalls in Lung Cancer and Mesotheliomaâ€• Seminars in Nuclear Medicine, 2021, 51, 458-473.	4.6	8
20	FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. Seminars in Nuclear Medicine, 2021, 51, 554-571.	4.6	9
21	Prognostic Value of Metabolic Imaging Data of 11C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Cancers, 2021, 13, 472.	3.7	3
22	Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. European Radiology, 2021, 31, 6001-6012.	4.5	53
23	PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer. Clinical and Translational Oncology, 2021, 23, 172-178.	2.4	16
24	How I faced my prostate cancer: a molecular biologistâ€™s perspective. Npj Precision Oncology, 2021, 5, 88.	5.4	1
25	Photopenic Defects in Gliomas With Amino-Acid PET and Relative Prognostic Value. Clinical Nuclear Medicine, 2021, 46, e36-e37.	1.3	11
26	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. Journal of Clinical Medicine, 2021, 10, 5160.	2.4	20
27	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. Frontiers in Oncology, 2021, 11, 772530.	2.8	14
28	Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group â€“ ESOI Joint Paper. Frontiers in Oncology, 2021, 11, 800547.	2.8	10
29	Diagnosis, Treatment Response, and Prognosis: The Role of ¹⁸F-DOPA PET/CT in Children Affected by Neuroblastoma in Comparison with ¹²³I-mIBG Scan: The First Prospective Study. Journal of Nuclear Medicine, 2020, 61, 367-374.	5.0	33
30	Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy. Clinical Lung Cancer, 2020, 21, 28-36.	2.6	5
31	Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas. PET Clinics, 2020, 15, 23-34.	3.0	11
32	Comparison Between ¹⁸F-FDG PETâ€“Based and CT-Based Criteria in Nonâ€“Small Cell Lung Cancer Patients Treated with Nivolumab. Journal of Nuclear Medicine, 2020, 61, 990-998.	5.0	44
33	Hyperprogressive Disease in Patients with Nonâ€“Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of ¹⁸F-FDG PET/CT. Journal of Nuclear Medicine, 2020, 61, 821-826.	5.0	73
34	The role of 11C-methionine PET in patients with negative diffusion-weighted magnetic resonance imaging: correlation with histology and molecular biomarkers in operated gliomas. Nuclear Medicine Communications, 2020, 41, 696-705.	1.1	3
35	Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1. Frontiers in Oncology, 2020, 10, 1090.	2.8	20
36	Imaging HCC treated with radioembolization: review of the literature and clinical examples of choline PET utility. Clinical and Translational Imaging, 2020, 8, 377-392.	2.1	0

#	Article	IF	Citations
37	Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters. Cancers, 2020, 12, 1373.	3.7	24
38	Impact of the COVID-19 crisis on imaging in oncological trials. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2054-2058.	6.4	11
39	Reply: Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT. Journal of Nuclear Medicine, 2020, 61, 1405.2-1405.	5.0	1
40	Metabolic Switch in Hepatocellular Carcinoma Patients Treated with Sorafenib: a Proof-of-Concept Trial. Molecular Imaging and Biology, 2020, 22, 1446-1454.	2.6	3
41	18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art. Current Radiopharmaceuticals, 2020, 13, 228-237.	0.8	17
42	Re: Michael S. Hofman, Nathan Lawrentschuk, Roslyn J. Francis, et al. Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. Lancet 2020;395:1208â€“16. European Urology, 2020, 78, e131-e132.	1.9	1
43	Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. Infectious Agents and Cancer, 2020, 15, 42.	2.6	29
44	Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors. Cancers, 2020, 12, 487.	3.7	29
45	The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 2020, 146, 1235-1243.	2.5	39
46	Non-FDG PET/CT. Recent Results in Cancer Research, 2020, 216, 669-718.	1.8	9
47	Evaluating response to immunotherapy with 18F-FDG PET/CT: where do we stand?. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1019-1021.	6.4	14
48	IRF4 instructs effector Treg differentiation and immune suppression in human cancer. Journal of Clinical Investigation, 2020, 130, 3137-3150.	8.2	103
49	The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. Current Radiopharmaceuticals, 2020, 13, 24-31.	0.8	6
50	Update on tumor metabolism and patterns of response to immunotherapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 175-185.	0.7	8
51	Cancer management in the era of immunotherapy: much more than meets the eye. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 141-142.	0.7	1
52	Nuclear Medicine Procedures in Neuroblastoma. , 2020, , 139-162.		0
53	Malignant Pleural Mesothelioma: 18F-FDG PET/CT for Response Assessment of Malignant Pleural Mesothelioma Following Immunotherapy. , 2020, , 43-53.		0
54	Hematologic Malignancies: PET/CT for Response Assessment of Hematologic Malignancies Following Immunotherapy. , 2020, , 81-90.		0

#	Article	IF	Citations
55	Does a 6-point scale approach to post-treatment 18F-FDG PET-CT allow to improve response assessment in head and neck squamous cell carcinoma? A multicenter study. European Journal of Hybrid Imaging, 2020, 4, 8.	1.5	4
56	Response Assessment and Follow-Up by Imaging in Breast Tumors. Medical Radiology, 2020, , 451-474.	0.1	0
57	Multimodality imaging of ectopic focus in Graves' Disease. Nuclear Medicine Review, 2020, 23, 45-46.	0.5	0
58	¹⁸F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. Leukemia and Lymphoma, 2019, 60, 367-375.	1.3	27
59	The Complexity and Fractal Geometry of Nuclear Medicine Images. Molecular Imaging and Biology, 2019, 21, 401-409.	2.6	14
60	Metabolism of Stem and Progenitor Cells: Proper Methods to Answer Specific Questions. Frontiers in Molecular Neuroscience, 2019, 12, 151.	2.9	20
61	Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1537-1545.	4.2	10
62	Diffusion-weighted imaging and loco-regional N staging of patients with colorectal liver metastases. European Journal of Surgical Oncology, 2019, 45, 347-352.	1.0	5
63	131I-MIBG Therapy of Malignant Neuroblastoma and Pheochromocytoma. , 2019, , 65-83.		2
64	Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors. World Neurosurgery, 2019, 126, e270-e280.	1.3	10
65	Frameless stereotactic biopsy for precision neurosurgery: diagnostic value, safety, and accuracy. Acta Neurochirurgica, 2019, 161, 967-974.	1.7	24
66	Prostate cancer imaging and therapeutic alternatives with highly specific molecular â€˜probesâ€™. BJU International, 2019, 124, 188-189.	2.5	2
67	Cost-effectiveness of second-line diagnostic investigations in patients included in the DANTE trial. Nuclear Medicine Communications, 2019, 40, 508-516.	1.1	3
68	In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma. Nuclear Medicine Communications, 2019, 40, 1179-1186.	1.1	4
69	FDG PET in response evaluation of bulky masses in paediatric Hodgkinâ€™s lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 97-106.	6.4	9
70	Deauville score: the Phoenix rising from ashes. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1043-1045.	6.4	8
71	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 540-557.	6.4	348
72	Prognostic Impact of Intratumoral Heterogeneity Based on Fractal Geometry Analysis in Operated NSCLC Patients. Molecular Imaging and Biology, 2019, 21, 965-972.	2.6	7

#	Article	IF	Citations
73	Siewert type I and II oesophageal adenocarcinoma: sensitivity/specificity of computed tomography, positron emission tomography and endoscopic ultrasound for assessment of lymph node metastases in groups of thoracic and abdominal lymph node stations. Interactive Cardiovascular and Thoracic Surgery, 2019, 28, 518-525.	1.1	6
74	FDG PET/CT for assessing tumour response to immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 238-250.	6.4	194
75	Response assessment of bone metastatic disease: seeing the forest for the trees RECIST, PERCIST, iRECIST, and PCWG-2. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 150-158.	0.7	7
76	Preliminary data on circulating tumor cells in metastatic NSCLC patients candidate to immunotherapy. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 282-295.	1.0	4
77	⁶⁸ Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study. Journal of Urology, 2018, 200, 95-103.	0.4	85
78	68Ga Prostate-specific Membrane Antigen PET/CT for Primary Diagnosis of Prostate Cancer: Complementary or Alternative to Multiparametric MR Imaging. Radiology, 2018, 287, 725-726.	7.3	10
79	Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer. Nuclear Medicine Communications, 2018, 39, 636-644.	1.1	14
80	Italian Multicenter Study on Accuracy of 18 F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e267-e273.	0.4	15
81	Is it time to change our vision of tumor metabolism prior to immunotherapy?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1072-1075.	6.4	47
82	⁶⁴CuCl₂ PET/CT in Prostate Cancer Relapse. Journal of Nuclear Medicine, 2018, 59, 444-451.	5.0	57
83	Incidental identification of osteoid osteoma by 68Ga-PSMA PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 509-510.	6.4	10
84	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, The, 2018, 19, e534-e545.	10.7	98
85	Role of 11C-choline PET/CT in radiation therapy planning of patients with prostate cancer. Nuclear Medicine Communications, 2018, 39, 951-956.	1.1	8
86	Prostate-specific antigen flare induced by 223RaCl2 in patients with metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2256-2263.	6.4	36
87	Guidelines on nuclear medicine imaging in neuroblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2009-2024.	6.4	94
88	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. Immunotherapy, 2018, 10, 797-805.	2.0	20
89	High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. Journal of Experimental Medicine, 2018, 215, 2520-2535.	8.5	250
90	Non-small cell lung carcinoma: understanding cancer microenvironment to drive immunotherapy and patientsâ€™ selection. Translational Cancer Research, 2018, 7, S568-S572.	1.0	4

#	Article	IF	Citations
91	Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1155-1164.	6.4	76
92	Report of the 6th International Workshop on PET in lymphoma. Leukemia and Lymphoma, 2017, 58, 2298-2303.	1.3	21
93	Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT. Nuclear Medicine Communications, 2017, 38, 340-346.	1.1	8
94	â€œThe simplest explanation is usually the correct oneâ€•â€“ Can Occamâ€™s razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1411-1412.	6.4	3
95	11C-Choline-Pet Guided Stereotactic Body Radiation Therapy for Lymph Node Metastases in Oligometastatic Prostate Cancer. Cancer Investigation, 2017, 35, 586-593.	1.3	14
96	Prognostic and predictive role of [¹⁸F]fluorodeoxyglucose positron emission tomography (FDGâ€PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with upâ€front pemetrexedâ€based chemotherapy. Cancer Medicine, 2017, 6, 2287-2296.	2.8	22
97	Refining the management of patients with hepatocellular carcinoma integrating 11C-choline PET/CT scan into the multidisciplinary team discussion. Nuclear Medicine Communications, 2017, 38, 826-836.	1.1	11
98	MP77-03 TARGETED 11C-CHOLINE PET/CT/TRUS SOFTWARE FUSION-GUIDED PROSTATE BIOPSY HAS IN MEN WITH PERSISTENTLY ELEVATED PSA AFTER PREVIOUS NEGATIVE BIOPSY. Journal of Urology, 2017, 197, .	0.4	0
99	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2310-2325.	6.4	46
100	Positron Emission Tomography-Computed Tomography for Patients with Recurrent Colorectal Liver Metastases: Impact on Restaging and Treatment Planning. Annals of Surgical Oncology, 2017, 24, 1029-1036.	1.5	17
101	Clinical staging of malignant pleural mesothelioma: current perspectives. Lung Cancer: Targets and Therapy, 2017, Volume 8, 127-139.	2.7	16
102	Targeted 11Câ€“choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy. European Journal of Hybrid Imaging, 2017, 1, 9.	1.5	9
103	Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study. Oncotarget, 2017, 8, 67696-67708.	1.8	16
104	Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer. Translational Cancer Research, 2017, 6, S982-S988.	1.0	4
105	Malignant pleural effusion (MPE) characterized with 11C-Methionine PET/CT before and after talc pleurodesis: interim evaluation of a prospective clinical trial. Annals of Oncology, 2016, 27, iv9.	1.2	0
106	Malignant pleural effusion (MPE) characterized with 11C-Methionine PET/CT before and after talc pleurodesis: interim evaluation of a prospective clinical trial. Annals of Oncology, 2016, 27, vi525.	1.2	1
107	Correlation of metabolic information on 18F-FDG PET with the tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) candidate to upfront surgery. Annals of Oncology, 2016, 27, iv8.	1.2	0
108	Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT. Clinical Nuclear Medicine, 2016, 41, e87-e92.	1.3	32

#	Article	IF	Citations
109	Cerebral Proliferative Angiopathy (CPA). Clinical Nuclear Medicine, 2016, 41, e527-e529.	1.3	6
110	Mo1576 PET/CT Standardized Uptake Value of 11C-choline as a Predictor of Long-Term Survival in Patients Operated for Hepatocellular Carcinoma: A Preliminary Report. Gastroenterology, 2016, 150, S1238.	1.3	0
111	Ability of 18F-DOPA PET/CT and fused 18F-DOPA PET/MRI to assess striatal involvement in paediatric glioma. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1664-1672.	6.4	25
112	Standardization of administered activities in paediatric nuclear medicine: the EANM perspective. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2275-2278.	6.4	4
113	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1954-1961.	6.4	122
114	Potential role of 18F-DOPA PET in neuroblastoma. Clinical and Translational Imaging, 2016, 4, 79-86.	2.1	7
115	Re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur Urol 2016;70:161â€“75. European Urology, 2016, 70, e112-e113.	1.9	5
116	SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors. Clinical Nuclear Medicine, 2015, 40, e271-e277.	1.3	9
117	Imaging biomarkers in primary brain tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 597-612.	6.4	23
118	Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 667-675.	6.4	42
119	Positron emission tomography in pediatric and adult sarcoma. Clinical and Translational Imaging, 2015, 3, 83-93.	2.1	0
120	Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1399-1407.	6.4	33
121	The diffusion-weighted imaging and 11-C-methionine positron emission tomography depiction of an endodermal cyst at the cervico-medullary junction. British Journal of Neurosurgery, 2015, 29, 739-741.	0.8	0
122	Diagnostic accuracy and impact on management of 18F-FDG PET and PET/CT in colorectal liver metastasis: a meta-analysis and systematic review. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 152-163.	6.4	124
123	What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients?. Acta OncolÃ³gica, 2014, 53, 990-992.	1.8	11
124	Usefulness of 64Cu-ATSM in Head and Neck Cancer. Clinical Nuclear Medicine, 2014, 39, e59-e63.	1.3	36
125	[11C]Choline PET/CT Impacts Treatment Decision Making in Patients With Prostate Cancer Referred for Radiotherapy. Clinical Genitourinary Cancer, 2014, 12, 155-159.	1.9	20
126	Imaging acute spinal myelitis with 18F-FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 399-400.	6.4	5

#	Article	IF	Citations
127	18F-DOPA PET/CT for assessment of response to induction chemotherapy in a child with high-risk neuroblastoma. Pediatric Radiology, 2014, 44, 355-361.	2.0	13
128	Prognostic value of 18F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1046-1056.	6.4	49
129	Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. Radiotherapy and Oncology, 2014, 112, 425-429.	0.6	42
130	11C-Methionine uptake in secondary brain epilepsy. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2014, 33, 234-236.	0.2	0
131	11C-Methionine uptake in secondary brain epilepsy. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2014, 33, 234-236.	0.0	5
132	Bone and Lymph Node Metastases From Neuroblastoma Detected by 18F-DOPA-PET/CT and Confirmed by Posttherapy 131I-MIBG but Negative on Diagnostic 123I-MIBG Scan. Clinical Nuclear Medicine, 2014, 39, e80-e83.	1.3	18
133	Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors. Tumori, 2014, 100, 636-644.	1.1	7
134	Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors. Tumori, 2014, 100, 636-44.	1.1	7
135	PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 365-84.	1.0	109
136	Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review. Critical Reviews in Oncology/Hematology, 2013, 88, 550-563.	4.4	52
137	Molecular Imaging in Oncology. Recent Results in Cancer Research, 2013, 187, 371-400.	1.8	6
138	The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma. Radiology and Oncology, 2013, 47, 97-183.	1.7	69
139	11C Choline PET Guided Salvage Radiotherapy with Volumetric Modulation Arc Therapy and Hypofractionation for Recurrent Prostate Cancer after HIFU Failure: Preliminary Results of Tolerability and Acute Toxicity. TCRT Express, 2013, 13, 395-401.	1.5	7
140	Cardiac and Acoustic Metastases in Relapsing Melanoma. Clinical Nuclear Medicine, 2013, 38, e85-e88.	1.3	6
141	Imaging struma ovarii by means of 124I-Na PET/CT. Nuclear Medicine Review, 2013, 16, 95-96.	0.5	1
142	PET/CT imaging in neuroblastoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2013, 57, 29-39.	0.7	23
143	Gallium-68 DOTANOC imaging in paraganglioma/pheochromocytoma: presentation of sample cases and review of the literature. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2013, 57, 134-45.	0.7	6
144	Feasibility of Carbidopa Premedication in Pediatric Patients: A Pilot Study. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 729-733.	1.0	11

#	Article	IF	Citations
145	18F-DOPA PET/CT in Neuroblastoma. Clinical Nuclear Medicine, 2012, 37, e73-e78.	1.3	63
146	The role of ¹⁸Fâ€FDG PET/CT in the metabolic characterization of lung nodules in pediatric patients with bone sarcoma. Pediatric Blood and Cancer, 2012, 59, 1206-1210.	1.5	55
147	FDG PET/CT predictive role in follicular lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 864-871.	6.4	32
148	Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 57-71.	6.4	111
149	Alveolar Rhabdomyosarcoma With Neuroendocrine Differentiation Detected by Ga-68 DOTA-NOC PET/CT. Clinical Nuclear Medicine, 2011, 36, 915-918.	1.3	4
150	Matched pairs dosimetry: 124I/131I metaiodobenzylguanidine and 124I/131I and 86Y/90Y antibodies. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 28-40.	6.4	39
151	Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkinâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1620-1627.	6.4	15
152	[11C]-choline PET/CT in imaging locally advanced prostate cancer. Nuclear Medicine Review, 2011, 14, 118-119.	0.5	2
153	Imaging with 11Carbon labelled PET tracers. Nuclear Medicine Communications, 2010, 31, 613-616.	1.1	3
154	Imaging with non-FDG PET tracers: outlook for current clinical applications. Insights Into Imaging, 2010, 1, 373-385.	3.4	13
155	FDGâ€“PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study. Annals of Oncology, 2010, 21, 1877-1883.	1.2	26
156	MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Annals of Oncology, 2010, 21, 1173-1178.	1.2	38
157	Positron-emission tomography in gynaecologic malignancies. Archives of Gynecology and Obstetrics, 2009, 280, 521-528.	1.7	16
158	C-Methionine PET/CT in Central Nervous System Tumours: A Review. Current Radiopharmaceuticals, 2009, 2, 160-164.	0.8	3
159	¹⁸F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 681-690.	1.0	29
160	Clinical significance of axillary findings in patients with lymphoma during follow-up with 18F-fluorodeoxyglucose-PET. Nuclear Medicine Communications, 2008, 29, 705-710.	1.1	8
161	Molecular imaging and targeted therapies in oncology: New concepts in treatment response assessment. A collection of cases. International Journal of Oncology, 1992, , .	3.3	1